Oral Azacitidine in Patients With Myelodysplastic Syndrome.

Shibusawa, Motoharu; Kidoguchi, Keisuke; Tanimoto, Tetsuya

Shibusawa, Motoharu; Kidoguchi, Keisuke; Tanimoto, Tetsuya.

Afiliação

Shibusawa M; Motoharu Shibusawa, MD, Department of Hematology, IMS Group Shinmatsudo Central General Hospital, Chiba, Japan; Keisuke Kidoguchi, MD, Saga-ken Medical Centre Koseikan, Saga, Japan; and Tetsuya Tanimoto, MD, Navitas Clinic Kawasaki, Kanagawa, Japan.
Kidoguchi K; Motoharu Shibusawa, MD, Department of Hematology, IMS Group Shinmatsudo Central General Hospital, Chiba, Japan; Keisuke Kidoguchi, MD, Saga-ken Medical Centre Koseikan, Saga, Japan; and Tetsuya Tanimoto, MD, Navitas Clinic Kawasaki, Kanagawa, Japan.
Tanimoto T; Motoharu Shibusawa, MD, Department of Hematology, IMS Group Shinmatsudo Central General Hospital, Chiba, Japan; Keisuke Kidoguchi, MD, Saga-ken Medical Centre Koseikan, Saga, Japan; and Tetsuya Tanimoto, MD, Navitas Clinic Kawasaki, Kanagawa, Japan.

J Clin Oncol ; 39(27): 3091-3092, 2021 09 20.

Article em En | MEDLINE | ID: mdl-34197214

Assuntos

Síndromes Mielodisplásicas; Antimetabólitos; Azacitidina/efeitos adversos; Humanos; Síndromes Mielodisplásicas/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google